N′-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 3, 2013, Pages 411-422

  Rodrigues, Juan R ^a,b   Charris, Jaime ^c   Camacho, José ^c   Barazarte, Arthur ^c   Gamboa, Neira ^c   Nitzsche, Bianca ^a,b   Höpfner, Michael ^a   Lein, Michael ^a,b,d   Jung, Klaus ^a,b   Abramjuk, Claudia ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

^c UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^d University Teaching Hospital   (Germany)

Author keywords

anti tumour effect; benzothiazole derivatives; neoangiogenesis; prostate cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; GELATINASE B; N' FORMYL 2 (5 NITROTHIOPHEN 2 YL)BENZOTHIAZOLE 6 CARBOHYDRAZIDE; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; HYDRAZINE DERIVATIVE; MMP9 PROTEIN, HUMAN; N'-FORMYL-2-(5-NITROTHIOPHEN-2-YL)BENZOTHIAZOLE-6-CARBOHYDRAZIDE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SPREADING; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; XENOGRAFT; ZYMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CELL MOTION; CELL SURVIVAL; DRUG EFFECT; DRUG SCREENING; MALE; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; TUMOR INVASION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; CELL ADHESION; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; HYDRAZINES; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873079915     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01607.x     Document Type: Article

References (48)

1. Siegel R, et al. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Stephenson AJ, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-3978.
3. Mottet N, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583.
4. Alam M, Siddiqui N,. Synthesis of new benzothiazole incorporated sulphonamides as potent anticonvulsants. Indian. J Heterocycl Chem 2004; 13: 361-364.
5. Latrofa A, et al. Structural modifications and antimicrobial activity of N-cycloalkenyl-2-acylalkylidene-2,3-dihydro-1,3-benzothiazoles. Farmaco 2005; 60: 291-297.
6. Ahmed K, et al. Recent advances on structural modifications of benzothiazoles and their conjugate systems as potential chemotherapeutics. Expert Opin Investig Drugs 2012; 21: 619-635.
7. Dubey R, et al. 2-(4-aminophenyl) benzothiazole: a potent and selective pharmacophore with novel mechanistic action towards various tumour cell lines. Mini Rev Med Chem 2006; 6: 633-637.
8. Lee YR, et al. Inhibition of TNF-alpha-mediated inflammatory responses by a benzodioxolylacetylamino-linked benzothiazole analog in human fibroblast-like synoviocytes. Biochem Biophys Res Commun 2011; 408: 625-629.
9. Stetler-Stevenson WG, Yu AE,. Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol 2001; 11: 143-152.
10. Denizot F, Lang R,. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-277.
11. Rodrigues J, et al. New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer. Pharm Res 2011; 28: 907-919.
12. Ruiz Y, et al. Cytotoxic and apoptosis-inducing effect of ent-15-oxo-kaur-16-en-19-oic acid, a derivative of grandiflorolic acid from Espeletia schultzii. Phytochemistry 2008; 69: 432-438.
13. Atienza JM, et al. Dynamic monitoring of cell adhesion and spreading on microelectronic sensor arrays. J Biomol Screen 2005; 10: 795-805.
14. Rodriguez LG, et al. Wound-healing assay. Methods Mol Biol 2005; 294: 23-29.
15. Nitzsche B, et al. Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours. Br J Cancer 2010; 103: 18-28.
16. Powell AA, et al. Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity. BMC Cancer 2006; 6: 219.
17. Mehta R, et al. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984; 770: 230-234.
18. McLaughlin JL, et al. Bench-top bioassay for the discovery of bioactive natural products: an update. In:, Rahman A, ed. Studies in Natural Products Chemistry. Amsterdam: Elsevier, 1991: 383-409.
19. Solis PN, et al. A microwell cytotoxicity assay using Artemia salina (brine shrimp). Planta Med 1993; 59: 250-252.
20. Nicklas W, et al. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim 2002; 36: 20-42.
21. Feldman JP, et al. A mathematical model for tumor volume evaluation using two-dimensions. J Appl Quant Methods 2009; 4: 455-462.
22. Rodrigues JR, et al. Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo. Invest New Drugs 2011; 30: 1426-1433.
23. Sancho P, et al. Dequalinium induces cell death in human leukemia cells by early mitochondrial alterations which enhance ROS production. Leuk Res 2007; 31: 969-978.
24. Wang XX, et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011; 32: 5673-5687.
25. Kumar B, et al. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68: 1777-1785.
26. Freedman VH, Shin SI,. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell 1974; 3: 355-359.
27. Bondock S, et al. Synthesis and antimicrobial activity of some new thiazole, thiophene and pyrazole derivatives containing benzothiazole moiety. Eur J Med Chem 2010; 45: 3692-3701.
28. Brantley E, et al. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)- 5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells. Cancer Chemother Pharmacol 2006; 58: 62-72.
29. Vicini P, et al. Benzisothiazolyliminothiazolidin-4-ones with chondroprotective properties: searching for potent and selective inhibitors of MMP-13. ChemMedChem 2011; 6: 1199-1202.
30. Christodoulou MS, et al. Synthesis and biological evaluation of imidazolo[2,1-b]benzothiazole derivatives, as potential p53 inhibitors. Bioorg Med Chem 2011; 19: 1649-1657.
31. Monks A, et al. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 2003; 63: 766-772.
32. Kok SH, et al. Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines. Bioorg Med Chem 2008; 16: 3626-3631.
33. Hu WP, et al. Synthesis, and biological evaluation of 2-(4-aminophenyl)benzothiazole derivatives as photosensitizing agents. Bioorg Med Chem 2010; 18: 6197-6207.
34. Tzanopoulou S, et al. Evaluation of Re and (99m)Tc complexes of 2-(4′-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals. J Med Chem 2010; 53: 4633-4641.
35. Sato G, et al. Assessment of potential mutagenic activities of a novel benzothiazole MAO-A inhibitor E2011 using Salmonella typhimurium YG1029. Mutat Res 2000; 472: 163-169.
36. Sterling KM, Jr, Cutroneo KR,. Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem 2004; 91: 423-429.
37. Nandekar PP, Sangamwar AT,. Cytochrome P450 1A1-mediated anticancer drug discovery: in silico findings. Expert Opin Drug Discov 2012; 7: 771-789.
38. Bradshaw TD, et al. Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 2002; 1: 239-246.
39. Leong CO, et al. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Cancer Ther 2004; 3: 1565-1575.
40. Mathijs K, et al. Assessing the metabolic competence of sandwich-cultured mouse primary hepatocytes. Drug Metab Dispos 2009; 37: 1305-1311.
41. Okegawa T, et al. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. Acta Biochim Pol 2004; 51: 445-457.
42. Hynes RO,. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002; 8: 918-921.
43. Chodniewicz D, Klemke RL,. Guiding cell migration through directed extension and stabilization of pseudopodia. Exp Cell Res 2004; 301: 31-37.
44. Pepper MS,. Manipulating angiogenesis. From basic science to the bedside. Arterioscler Thromb Vasc Biol 1997; 17: 605-619.
45. Birkedal-Hansen H, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4: 197-250.
46. Folgueras AR, et al. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411-424.
47. Huang S, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002; 94: 1134-1142.
48. Cifone MA, Fidler IJ,. Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci U S A 1980; 77: 1039-1043.